Clinical Trials Logo

Clinical Trial Summary

We aimed to evaluate the hypothalamus-pituitary-adrenal axis in autosomal dominant polycystic kidney disease (ADPKD) patients. Twenty two ADPKD patients and 27 healthy subjects were enrolled.


Clinical Trial Description

CONTEXT: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and extrarenal manifestations may be observed in many organ systems. Hypothalamus-pituitary-adrenal axis in patients with ADPKD was not evaluated extensively.

OBJECTIVE: We aimed to evaluate the hypothalamus-pituitary-adrenal axis in ADPKD patients.

METHODS: Twenty two ADPKD patients and 27 healthy subjects were enrolled. Basal dehydroepiandrosterone-sulfate (DHEAS) levels and cortisol and dehydroepiandrosterone responses to low dose short adrenocorticotropin stimulation test were assessed. Correlation analyses of these parameters with glomerular filtration rates, renal volumes and pain characteristics in patients with ADPKD were done. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00598377
Study type Interventional
Source Istanbul University
Contact
Status Completed
Phase N/A
Start date September 2006
Completion date September 2007

See also
  Status Clinical Trial Phase
Completed NCT02933268 - High Water Intake in Polycystic Kidney Disease N/A
Completed NCT00759369 - Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) N/A
Completed NCT01039987 - Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease N/A
Completed NCT03717883 - ADPKD Alterations in Hepatic Transporter Function
Recruiting NCT05193981 - A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
Completed NCT03487913 - The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 2
Not yet recruiting NCT06435858 - Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease Phase 4
Recruiting NCT05190744 - PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration Phase 2
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Recruiting NCT04344769 - Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Active, not recruiting NCT02848521 - A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
Completed NCT01451827 - 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2
Completed NCT01336972 - Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2
Completed NCT01210560 - Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Phase 2
Completed NCT02134899 - The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients Phase 3
Active, not recruiting NCT02729662 - Efficacy of Tolvaptan on ADPKD Patients N/A
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05288998 - Intrarenal Microvasculature in ADPKD
Recruiting NCT04939935 - Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Phase 3
Withdrawn NCT01988038 - Repository Study of Autosomal Dominant Polycystic Kidney Disease N/A